Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
92 hedge funds and large institutions have $282M invested in Paratek Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 14 closing their positions.
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
27% more capital invested
Capital invested by funds: $222M → $282M (+$59.9M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
7% more funds holding
Funds holding: 86 → 92 (+6)
74% less call options, than puts
Call options by funds: $388K | Put options by funds: $1.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.05M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.25M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$2.04M |
| 4 |
NC
Nexthera Capital
New York
|
+$1.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAI
General American Investors
New York
|
-$3.6M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$2.39M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$1.33M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$844K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$781K |
PRTK Hedge Fund Activity: Q4 2016 in Review
92 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2016, worth a combined $282M — up 27% from $222M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PRTK positions and 14 closed out — a net gain of 6 holders — while 27 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $5.05M. The largest seller was General American Investors, cutting an estimated $3.6M.
- 92 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2016, up from 86 in Q3 2016.
- Funds reported $282M of Paratek Pharmaceuticals, Inc. stock for Q4 2016, up 27% quarter-over-quarter.
- 20 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2016 and 14 closed out, a net change of +6 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $5.05M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2016 was General American Investors, an estimated $3.6M sold.
Based on aggregated 13F filings for Q4 2016.